<DOC>
	<DOCNO>NCT00241098</DOCNO>
	<brief_summary>This study evaluate response patient hypertension early stage heart failure valsartan .</brief_summary>
	<brief_title>The VALIDATE Study Valsartan Patients With Early Stage Heart Failure</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Heart Failure</mesh_term>
	<mesh_term>Valsartan</mesh_term>
	<criteria>Male female 2585 year age , inclusive Past diagnosis hypertension min 1 year Patients establish treatment regimen hypertension one agent minimum period 2 month BP consider adequately control DBP &lt; 90mmHg Elevated BNP level bedside test ( 62pg/ml ) validation separate blood sample ( 40pg/ml ) central laboratory LV ejection fraction ³ 45 % LVH define myocardial mass ³ 116 g /m2 males 104 g/m2 female At least one follow parameter diastolic dysfunction E/A &lt; 1 patient young 55 year &lt; 0.8 patient whose age ³ 55 year ( full year ) , DT &gt; 220 m , IVRT &gt; 90 m • Present use ACE inhibitor Other protocoldefined exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>55 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2006</verification_date>
	<keyword>HYPERTENSION</keyword>
	<keyword>HEART FAILURE</keyword>
	<keyword>PEPTIDE</keyword>
	<keyword>valsartan</keyword>
</DOC>